Table 4. Meta-analysis of BCL-2 promoter polymorphisms and cancer prognosis.

Genetic model	No.ofstudies	PQ	I2	HR	95% CI	PZ	Model
rs2279115
Total	13(4013/5319)
CC vs. CA		0.011	59.6%	1.09	1.03,1.51	<0.001	Random-effects model
CC vs. AA		0.018	58.5%	1,18	1.07,1.66	<0.001	Random-effects model
CA vs. AA		0.677	0.00%	1.31	1.12,2.61	<0.001	Fixed-effects model
CC vs. CA+AA		0.000	84.8%	1.26	1.16,1.71	<0.001	Random-effects model
Asia	6(2813/3124)
CC vs. CA		0.000	55.5%	1.17	1.01,1.41	<0.001	Random-effects model
CC vs. AA		0.000	38.4%	1.50	1.01,2.15	<0.001	Fixed-effects model
CA vs. AA		0.000	55.1%	1.38	1.03,1.87	<0.001	Random-effects model
CC vs. CA+AA		0.000	53.4%	1.21	1.06,1.75	<0.001	Random-effects model
Caucasian	7(1200/2195)
CC vs. CA		0.651	0.0%	1.01	0.90,1.13	0.878	Fixed-effects model
CC vs. AA		0.392	5.2%	1.04	0.89,1.21	0.937	Fixed-effects model
CA vs. AA		0.299	15.2%	1.07	0.92,1.45	0.430	Fixed-effects model
CC vs. CA+AA		0.180	29.9%	1.35	0.72,2.52	0.829	Fixed-effects model
rs1801018	5(1889/2110)
AA vs. AG+GG		0.088	43.6%	0.95	0.68,1.36	0.547	Fixed-effects model
AG vs. GG		0.610	0.0%	1.51	0.74,2.13	0.429	Fixed-effects model